Skip to main content
SpringerLink
Log in

Anticoagulation Reversal Guide and Reversal Agents

  • Chapter
  • First Online:
Book cover Precision Anticoagulation Medicine

  • 1008 Accesses

Abstract

To prevent clot formation or treat thrombosis, anticoagulants disrupt normal hemostasis by multiple mechanisms. In the context of active bleeding with or without an over-dosage, or when an urgent situation necessitates immediate hemostasis, it is important to reverse the action of therapeutic anticoagulants. This chapter illustrates the different modalities and approaches to reverse the action of commonly used therapeutic anticoagulants.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

3F-PCC:

Three-factor prothrombin complex concentrate

4F-PCC:

Four-factor prothrombin complex concentrate

aPCC:

Activated prothrombin complex concentrate

ASCO:

American Society of Clinical Oncology

CAT:

Cancer-associated thrombosis

CrCl:

Creatinine clearance

CVC:

Central venous catheter

DOACs:

Direct oral anticoagulants

DVT:

Deep vein thrombosis

FEIBA:

Factor eight inhibitor bypassing activity

FFP:

Fresh frozen plasma

INR:

International normalized ratio

IU:

International unit

LMWH:

Low-molecular-weight heparin

NCCN:

National Comprehensive Cancer Network

PCC:

Prothrombin complex concentrate

PE:

Pulmonary embolism

PTT:

Partial thromboplastin time

rFVIIa:

Recombinant activated factor VII

S/D:

Solvent and detergent

U:

Unit

UFH:

Unfractionated heparin

VH:

Vapor heat

VTE:

Venous thromboembolism

WFI:

Water for injection

References

  1. Ferreira JL, Wipf JE. Pharmacologic therapies in anticoagulation. Med Clin North Am. 2016;100(4):695–718.

    Article  Google Scholar 

  2. Holzmacher JL, Sarani B. Indications and methods of anticoagulation reversal. Surg Clin N Am. December 2017;97(6):1291–305.

    Article  Google Scholar 

  3. PRODUCT MONOGRAPH PrFRAXIPARINE®Aspen Pharmacare Canada Inc 111 Queen Street East, Suite 450, Toronto, Ontario, M5C 1S2 Submission. Control No: 195973 Date of Revision: July 11, 2017.

    Google Scholar 

  4. PRODUCT MONOGRAPH Prinnohep® tinzaparin sodium sterile solution for SC injection. LEO Pharma Inc Thornhill, ON L3T 7W8 www.leo-pharma.com/canada Date of Revision: February 16, 2016.

  5. Argatroban prescription information, ARGATROBAN INJECTION in 0.9% Sodium Chloride, for intravenous infusion U.S. Approval: 2000.

    Google Scholar 

  6. http://thrombosiscanada.ca/wp-content/uploads/2016/05/Anticoagulant-relatedBleedMgmntOSv.12.pdf.

  7. Tomaselli GF, et al. ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol. 2017;70:3042.

    Article  Google Scholar 

  8. Brighton T. New oral anticoagulant drugs - mechanisms of action. Aust Prescr. 2010;33(2):38–41.

    Article  Google Scholar 

  9. Patriquin C, Crowther M. Treatment of Warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol. 2011;4(6):657–67.

    Article  CAS  Google Scholar 

  10. Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, Crowther M, Vandvik PO, Eikelboom JW, McDonagh MS, Lewis SZ, Gutterman DD, Cook DJ, Schünemann HJ. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):53S–70S.

    Article  CAS  Google Scholar 

  11. Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A. The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):897–909.

    Article  CAS  Google Scholar 

  12. Bromfield SM, Wilde E, Smith DK. Heparin sensing and binding - taking supramolecular chemistry towards clinical applications. Chem Soc Rev. 2013 Dec 7;42(23):9184–95.

    Article  CAS  Google Scholar 

  13. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1964129-33f4-4e4e-86e3-8e6a4e65bd83.

  14. Bebulin (factor IX complex) [prescribing information]. Westlake Village, CA: Baxter Healthcare; September 2015.

    Google Scholar 

  15. PRODUCT MONOGRAPH IMMUNINE VH (Factor IX Concentrate (Human), Vapor Heated, IMMUNO) Freeze-dried powder with diluent for intravenous injection 480–720 IU1 /5 mL, Pharmacopeial Hemostatic Shire Pharma Canada ULC 22 Adelaide Street West, Suite 3800 Toronto Ontario M5H. 4E3 Submission Control No: 214296 Date of Approval: April 23, 2018.

    Google Scholar 

  16. Profilnine (factor IX complex) [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc; March 2017.

    Google Scholar 

  17. Masotti L, Di Napoli M, Godoy DA, Rafanelli D, Liumbruno G, Koumpouros N, Landini G, Pampana A, Cappelli R, Poli D, Prisco D. The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. Int J Stroke. 2011 Jun;6(3):228–40.

    Article  Google Scholar 

  18. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM, Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181(9):492–7.

    Article  Google Scholar 

  19. Herzog E, Kaspereit F, Krege W, Niebl P. Stefan Schulte and Gerhard Dickneite four-factor Prothrombin Complex Concentrate (4F-PCC) is superior to three-factor Prothombin Complex Concentrates (3F-PCC) for reversal of Coumarin anticoagulation blood, vol. 124; 2014. p. 1472.

    Google Scholar 

  20. HIGHLIGHTS OF PRESCRIBING INFORMATION. KCENTRA® (Prothrombin Complex Concentrate (Human)) for Intravenous Use, Lyophilized Powder for Reconstitution. Initial U.S. Approval: 2013

    Google Scholar 

  21. PRODUCT MONOGRAPH Beriplex® P/N 500 / Beriplex® P/N 1000 Powder and solvent for solution for injection Human Prothrombin Complex. CSL Behring Canada, Inc. 55 Metcalfe Street, Suite 1460 Ottawa, Ontario K1P 6 L5 Date of Revision: September 08, 2017 Date of Approval: September 25, 2017.

    Google Scholar 

  22. PRODUCT MONOGRAPH octaplex® Human Prothrombin Complex, freeze dried powder and solvent for solution for injection. Manufactured by: Octapharma Pharmazeutika Produktionsges m.b.H. Oberlaaer Strasse 235 A-1100 Vienna, Austria. Date of Approval: November 3, 2017.

    Google Scholar 

  23. PROTHROMBIN COMPLEX CONCENTRATE (PCC) Comparison table, Canadian Blood Services, 2011-06-30 Page 1 .

    Google Scholar 

  24. Barton CA, Hom M, Johnson NB, Case J, Ran R, Schreiber M. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa. Am J Surg. 2018;215(5):775–9.

    Article  Google Scholar 

  25. Abildgaard CF, Penner JA, Watson-Williams EJ. Anti-inhibitor coagulant complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood. 1980;56:978–84.

    Article  CAS  Google Scholar 

  26. FEIBA (Anti-Inhibitor Coagulant Complex) for intravenous use, lyophilized powder for solution, vapour heated, prescibing information. Westlake Village: Baxter Healthcare Corporation; 2005.

    Google Scholar 

  27. Dibu JR, Weimer JM, Ahrens C, Manno E, Frontera JA. The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage. Neurocrit Care. 2016;24(3):413–9.

    Article  CAS  Google Scholar 

  28. Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thromb J. 2017;15:6.

    Article  Google Scholar 

  29. Dager WE, King JH, Regalia RC, Williamson D, Gosselin RC, White RH, Tharratt RS, Albertson TE. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006;26(8):1091–8.

    Article  CAS  Google Scholar 

  30. Young G, Yonekawa KE, Nakagawa P, Blain R, Lovejoy AE, Diane J. Nugent recombinant factor VIIa reverses the anticoagulant effects of Argatroban, Bivalirudin, Fondaparinux, Enoxaparin, and Heparin as assessed Ex Vivo by thromboelastography. Blood. 2004;104:1867.

    Article  Google Scholar 

  31. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrPRAXBIND® Idarucizumab Solution for Infusion or bolus Injection, 5 g/dose Professed Standard Antidote for Pradaxa® Boehringer Ingelheim (Canada) Ltd. 5180 South Service Road Burlington, Ontario L7L 5H4 Date of Approval: June 28, 2018.

    Google Scholar 

  32. Pollack CV. Idarucizumab for dabigatran reversal: updated results of the RE-VERSE AD Study. Presented at 2016 American Heart Association Scientific Sessions 2016; New Orleans, LA.

    Google Scholar 

  33. ANDEXXA® Product monograph, (coagulation factor Xa (recombinant), inactivated-zhzo) Lyophilized Powder for Solution For Intravenous Injection Initial U.S. Approval: 2018.

    Google Scholar 

  34. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr, ANNEXA-4 Investigators. Full study report of Andexanet Alfa for Bleeding associated with factor Xa inhibitors. N Engl J Med. 2019; https://doi.org/10.1056/NEJMoa1814051.

    Article  CAS  Google Scholar 

  35. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, ANNEXA-4 Investigators. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131–41.

    Article  CAS  Google Scholar 

  36. Schubert-Zsilavecz, M, Wurglics, M, Ciraparantag. Neue Arzneimittel Herbst 2015 (in German).

    Google Scholar 

  37. Ansell JE. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J Thromb Thrombolysis. 2016;41(2):248–52.

    Article  CAS  Google Scholar 

  38. Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res. 2016;146:113–8.

    Article  CAS  Google Scholar 

  39. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, Dishy V, Lanz HJ, Mercuri MF, Noveck RJ, Costin JC. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 2017;117(2):238–45.

    Article  Google Scholar 

  40. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141–2.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saskatoon Cancer Centre and Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

    Waleed Sabry, Caroline Hart & Hadi Goubran

Authors
  1. Waleed Sabry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline Hart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hadi Goubran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Waleed Sabry .

Editor information

Editors and Affiliations

  1. Saskatoon Cancer Centre College of Medicine University of Saskatchewan, Saskatoon, SK, Canada

    Hadi Goubran

  2. Faculty of Medicine Cairo University, Giza, Egypt

    Gaafar Ragab

  3. College of Human Medicine Michigan State University, East Lansing, MI, USA

    Suzy Hassouna

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sabry, W., Hart, C., Goubran, H. (2020). Anticoagulation Reversal Guide and Reversal Agents. In: Goubran, H., Ragab, G., Hassouna, S. (eds) Precision Anticoagulation Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-25782-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25782-8_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25781-1

  • Online ISBN: 978-3-030-25782-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation